15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Giant HECT E3 Ubiquitin Ligase HERC1 Is Aberrantly Expressed in Myeloid Related Disorders and It Is a Novel BCR-ABL1 Binding Partner

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Simple Summary

          The pathological role/s of the HERC family members has recently been initiated to be explored in few solid tumors and the assessment of their transcript amount reveals that they might act as effective prognostic factors. However, evidence concerning the non-solid tumors, and especially myeloid related neoplasms, is currently lacking. In the present article for the first time we provide original data for a clear and well-defined association between the gene expression level of a giant HERC E3 ubiquitin ligase family member, HERC1, and some myeloid related disorders, namely Acute Myeloid Leukemia, Myeloproliferative neoplasms and Chronic Myeloid Leukemia. Furthermore, our findings unveil that the HERC1 protein physically interacts, likely forming a very large supramolecular complex, and it is a putative BCR-ABL1 tyrosine kinase substrate. We hope that this work will contribute to the advance of our understanding of the roles played by the giant HERCs in myeloid related neoplasms.

          Abstract

          HERC E3 subfamily members are parts of the E3 ubiquitin ligases and key players for a wide range of cellular functions. Though the involvement of the Ubiquitin Proteasome System in blood disorders has been broadly studied, so far the role of large HERCs in this context remains unexplored. In the present study we examined the expression of the large HECT E3 Ubiquitin Ligase, HERC1, in blood disorders. Our findings revealed that HERC1 gene expression was severely downregulated both in acute and in chronic myelogenous leukemia at diagnosis, while it is restored after complete remission achievement. Instead, in Philadelphia the negative myeloproliferative neoplasm HERC1 level was peculiarly controlled, being very low in Primary Myelofibrosis and significantly upregulated in those Essential Thrombocytemia specimens harboring the mutation in the calreticulin gene. Remarkably, in CML cells HERC1 mRNA level was associated with the BCR-ABL1 kinase activity and the HERC1 protein physically interacted with BCR-ABL1. Furthermore, we found that HERC1 was directly tyrosine phosphorylated by the ABL kinase. Overall and for the first time, we provide original evidence on the potential tumor-suppressing or -promoting properties, depending on the context, of HERC1 in myeloid related blood disorders.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: not found
          • Article: not found

          Acute Myeloid Leukemia.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Ubiquitination in disease pathogenesis and treatment.

            Ubiquitination is crucial for a plethora of physiological processes, including cell survival and differentiation and innate and adaptive immunity. In recent years, considerable progress has been made in the understanding of the molecular action of ubiquitin in signaling pathways and how alterations in the ubiquitin system lead to the development of distinct human diseases. Here we describe the role of ubiquitination in the onset and progression of cancer, metabolic syndromes, neurodegenerative diseases, autoimmunity, inflammatory disorders, infection and muscle dystrophies. Moreover, we indicate how current knowledge could be exploited for the development of new clinical therapies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ubiquitin Ligases: Structure, Function, and Regulation.

              Ubiquitin E3 ligases control every aspect of eukaryotic biology by promoting protein ubiquitination and degradation. At the end of a three-enzyme cascade, ubiquitin ligases mediate the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to specific substrate proteins. Early investigations of E3s of the RING (really interesting new gene) and HECT (homologous to the E6AP carboxyl terminus) types shed light on their enzymatic activities, general architectures, and substrate degron-binding modes. Recent studies have provided deeper mechanistic insights into their catalysis, activation, and regulation. In this review, we summarize the current progress in structure-function studies of ubiquitin ligases as well as exciting new discoveries of novel classes of E3s and diverse substrate recognition mechanisms. Our increased understanding of ubiquitin ligase function and regulation has provided the rationale for developing E3-targeting therapeutics for the treatment of human diseases.
                Bookmark

                Author and article information

                Journal
                Cancers (Basel)
                Cancers (Basel)
                cancers
                Cancers
                MDPI
                2072-6694
                19 January 2021
                January 2021
                : 13
                : 2
                : 341
                Affiliations
                [1 ]Department of Clinical and Biological Science, Medical School, University of Torino, 10043 Orbassano, Italy; muhammad.ali79@ 123456edu.unito.it (M.S.A.); cristina.panuzzo@ 123456unito.it (C.P.); chiara.calabrese@ 123456unito.it (C.C.); alessandro.maglione@ 123456unito.it (A.M.); daniela.cilloni@ 123456unito.it (D.C.); giuseppe.saglio@ 123456unito.it (G.S.)
                [2 ]Department of Health Sciences, University of Milano-Bicocca, 20900 Monza, Italy; rocco.piazza@ 123456unimib.it
                [3 ]Department of Oncology, Medical School, University of Torino, 10043 Orbassano, Italy
                Author notes
                [†]

                Share the last authorship.

                Author information
                https://orcid.org/0000-0001-6234-8369
                https://orcid.org/0000-0001-7153-2248
                https://orcid.org/0000-0003-4198-9620
                https://orcid.org/0000-0001-6346-4791
                https://orcid.org/0000-0003-4686-0068
                https://orcid.org/0000-0003-3170-2817
                Article
                cancers-13-00341
                10.3390/cancers13020341
                7832311
                33477751
                eb95711e-941b-4aa8-a6bd-93b99c877bef
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 31 December 2020
                : 14 January 2021
                Categories
                Article

                e3 ubiquitin ligases,ubiquitin proteasome system,myeloid neoplasms,bcr-abl1,herc1,gene expression,protein–protein interaction

                Comments

                Comment on this article